ATE85809T1 - Herstellung des menschlichen von-willebrandfaktors durch rekombinante dns. - Google Patents

Herstellung des menschlichen von-willebrandfaktors durch rekombinante dns.

Info

Publication number
ATE85809T1
ATE85809T1 AT86200518T AT86200518T ATE85809T1 AT E85809 T1 ATE85809 T1 AT E85809T1 AT 86200518 T AT86200518 T AT 86200518T AT 86200518 T AT86200518 T AT 86200518T AT E85809 T1 ATE85809 T1 AT E85809T1
Authority
AT
Austria
Prior art keywords
von willebrand
sequence
vwf
pro
cdna
Prior art date
Application number
AT86200518T
Other languages
English (en)
Inventor
Hans Pannekoek
Cornelis Lammert Verwey
Paul Johan Diergaarde
Margaretha Hendrika L Hart
Original Assignee
Stichting Vrienden Van De Stic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19845776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE85809(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stichting Vrienden Van De Stic filed Critical Stichting Vrienden Van De Stic
Application granted granted Critical
Publication of ATE85809T1 publication Critical patent/ATE85809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT86200518T 1985-04-01 1986-03-26 Herstellung des menschlichen von-willebrandfaktors durch rekombinante dns. ATE85809T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8500961A NL8500961A (nl) 1985-04-01 1985-04-01 Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
EP86200518A EP0197592B1 (de) 1985-04-01 1986-03-26 Herstellung des menschlichen von-Willebrand-Faktors durch rekombinante DNS

Publications (1)

Publication Number Publication Date
ATE85809T1 true ATE85809T1 (de) 1993-03-15

Family

ID=19845776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86200518T ATE85809T1 (de) 1985-04-01 1986-03-26 Herstellung des menschlichen von-willebrandfaktors durch rekombinante dns.

Country Status (6)

Country Link
EP (1) EP0197592B1 (de)
JP (2) JP3123650B2 (de)
AT (1) ATE85809T1 (de)
CA (1) CA1341095C (de)
DE (1) DE3687761T2 (de)
NL (1) NL8500961A (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
AU591671B2 (en) * 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
AU602487B2 (en) * 1985-05-16 1990-10-18 Meloy Laboratories, Inc. Molecular cloning of cDNA for human factor VIIIR (von Willebrand factor)
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
WO1988005825A1 (en) * 1987-01-30 1988-08-11 Biogen N.V. A method for producing factor viii in high yield
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US6008193A (en) * 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
ATE305053T1 (de) * 1996-07-19 2005-10-15 Univ Michigan Für den von willebrand faktor der hunde kodierende dna und verfahren zu ihrer verwendung
US6780583B1 (en) 1996-07-19 2004-08-24 Board Of Trustees Operating Michigan State University DNA encoding canine von willebrand factor and methods of use
US6767707B2 (en) 1996-07-19 2004-07-27 University Of Michigan DNA encoding canine von willebrand factor and methods of use
US6410237B1 (en) 1997-07-18 2002-06-25 Board Of Trustees Operating Michigan State University DNA encoding canine von Willebrand factor and methods of use
AU5134600A (en) * 1999-05-14 2000-12-05 Incyte Genomics, Inc. Full-length molecules expressed in human tissues
WO2006029258A2 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
SG156618A1 (en) 2004-09-07 2009-11-26 Archemix Corp Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
DK2590998T3 (en) 2010-07-08 2018-02-12 Baxalta GmbH PROCEDURE FOR PREPARING RECOMBINANT vWF WITH HIGH MOLECULE WEIGHT IN CELL CULTURE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2079292A (en) * 1980-07-05 1982-01-20 Speywood Lab Ltd Blood Clotting Factor Production

Also Published As

Publication number Publication date
CA1341095C (en) 2000-09-12
EP0197592A1 (de) 1986-10-15
NL8500961A (nl) 1986-11-03
JPS6228A (ja) 1987-01-06
EP0197592B1 (de) 1993-02-17
JP2000342290A (ja) 2000-12-12
DE3687761T2 (de) 1993-06-09
JP3123650B2 (ja) 2001-01-15
DE3687761D1 (de) 1993-03-25

Similar Documents

Publication Publication Date Title
ATE85809T1 (de) Herstellung des menschlichen von-willebrandfaktors durch rekombinante dns.
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
EP0401384A4 (en) Chemically modified granulocyte colony stimulating factor
MX166499B (es) Interferon recombinante inmune humano y composicion farmaceutica que lo incluye
DK0454898T3 (da) Glycosaminoglycan-modificeret protein, fremgangsmåde til fremstilling af proteinet, farmaceutiske præparater indeholdende proteinet samt anvendelse af proteinet
DE68928380D1 (de) Expression von menschlichen Serumalbumin in methylotrophischen Hefen
KR890000517A (ko) 하이브리드 단백질 c 및 이의 제조방법
PT80300A (de) Herstellung von polypeptiden mit human-gammainterferonaktivitat
ATE501254T1 (de) P- selectin ligandenprotein
DE69123106D1 (de) Polypeptid, das zur Interaktion mit Thrombin fähig ist
FI102293B1 (fi) Ihmisen interleukiini-3:n molekulaarinen kloonaus ja ilmentäminen
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DE69333412D1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
PT81345B (pt) Processo para a preparacao de novos peptideos activos sobre o sistema nervoso central com accao sobre o sistema colinergico, e de composicoes farmaceuticas contendo estes compostos
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
FR2624854B1 (fr) Nouveaux sulfonamides du benzylidene camphre derivant d'aminoacides et leur application en cosmetique, notamment en tant que filtres solaires
FI93843C (fi) Menetelmä angiogeenisen tekijän tuottamiseksi
DE69225473D1 (de) Vom endonukleaseprotein des menschlichen immunschwäche virus abgeleitete polypeptide
DE58909261D1 (de) Ancrod-proteine, ihre herstellung und verwendung.
ATE108207T1 (de) Polypeptide und dafür kodierende dna.
KR870004142A (ko) 인터로이킨-2 유도체의 제조방법
ATE86499T1 (de) Vorbeugende massnahmen zur verhinderung der ''komplexen respiratorischen erkrankung bei rindern'' durch verabreichung von interferon.
KR900701834A (ko) 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus
ATE98679T1 (de) Herstellung des hblv-virus in der hsb-2 zelllinie.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time